Palisade Bio (PALI) Net Income towards Common Stockholders (2010 - 2026)

Palisade Bio (PALI) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$10.7 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$10.7 million, down 382.02% year-over-year; the trailing twelve-month figure through Mar 2026 was -$26.4 million (down 100.15% YoY), and the FY2025 annual result was -$18.1 million, down 21.48% from the prior year.
• Net Income towards Common Stockholders eased to -$10.7 million in Q1 2026 per PALI's latest filing, from -$10.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$2.2 million in Q1 2025 and troughed at -$10.7 million in Q1 2026.
• A 5-year average of -$4.1 million and a median of -$3.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders jumped 92.62% in 2022, then sank 382.02% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$3.9 million in 2022, then grew by 18.0% to -$3.2 million in 2023, then retreated by 7.19% to -$3.4 million in 2024, then sank by 194.92% to -$10.0 million in 2025, then fell by 7.67% to -$10.7 million in 2026.
• Business Quant data shows PALI's Net Income towards Common Stockholders at -$10.7 million in Q1 2026, -$10.0 million in Q4 2025, and -$2.9 million in Q3 2025.